Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1090-1098

  Favaloro, James ^a   Brown, Ross ^a   Aklilu, Esther ^a   Yang, Shihong ^a   Suen, Hayley ^a   Hart, Derek ^b   Fromm, Phillip ^b   Gibson, John ^a   Khoo, Liane ^a   Ho, P Joy ^a   Joshua, Douglas ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

Dexamethasone; IMiDs; Immunoregulation; Multiple myeloma; Treg cells

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3; LEUKOCYTE ANTIGEN;

ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; TREG TH17 BALANCE; UPREGULATION; CASE CONTROL STUDY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; METABOLISM; PARAPROTEINEMIA; PHENOTYPE;

ANTIGENS, CD; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PHENOTYPE; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84899727660     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.825905     Document Type: Article

References (43)

1. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007; 178: 6730-6733.
2. Joshua DE, Brown RD, Ho PJ, et al. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008; 8: 283-286.
3. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4-T reg cells. J Exp Med 2006; 203: 1701-1711.
4. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329-341.
5. Beyer M, Kochanek M, Giese T, et a l. I n vivo peripheral expansion of naive CD4-CD25high FoxP3-regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940-3949.
6. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
7. Prabhala R H, Neri P, Bae J E, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107: 301-304.
8. Feyler S, von Lilienfeld-Toal M, Jarmin S, et al. CD4(-)CD25(-) FoxP3(-) regulatory T cells are increased whilst CD3(-)CD4(-) CD8(-)alphabetaTCR(-) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009; 144: 686-695.
9. Gupta R, Ganeshan P, Hakim M, et al. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 2011; 35: 874-878.
10. Braga WM, Atanackovic D, Colleoni GW. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012; 2012: 293479.
11. Quach H, Ritchie D, Neeson P, et al. Regulatory T cells (Treg) are depressed in patients with relapsed/refractory multiple myeloma (MM) and increases towards normal ranges in responding patients treated with lenalidomide (LEN). Blood 2008; 112(Suppl. 1): Abstract 1696.
12. Law JP, Hirschkorn DF, Owen RE, et al. The importance of Foxp3 antibody and fi xation/permeabilization buff er combinations in identifying CD4-CD25-Foxp3-regulatory T cells. Cytometry A 2009; 75: 1040-1050.
13. Sattui S, de la Flor C, Sanchez C, et al. Cryopreservation modulates the detection of regulatory T cell markers. Cytometry B Clin Cytom 2012; 82: 54-58.
14. Minnema M C, van der Veer M S, Aarts T, et al. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4-Foxp3-T cells. Leukemia 2009; 23: 605-607.
15. Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012; 53: 1406-1408.
16. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic selftolerance maintained by CD25(-)CD4(-) regulatory T cells constitutively expressing cytotoxic T lymphocyte-Associated antigen 4. J Exp Med 2000; 192: 303-310.
17. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543-9553.
18. Le N T, Chao N. R egulating regulatory T cells. B one Marrow Transplant 2007; 39: 1-9.
19. Zheng Y, Manzotti CN, Burke F, et al. Acquisition of suppressive function by activated human CD4-CD25-T cells is associated with the expression of CTLA-4 not FoxP3. J Immunol 2008; 181: 1683-1691.
20. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: How do they suppress immune responses? Int Immunol 2009; 21: 1105-1111.
21. Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012; 7: E35981.
22. Lin YC, Chang LY, Huang CT, et al. effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J Immunol 2009; 182: 6095-6104.
23. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
24. Shiratori T, Miyatake S, Ohno H, et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-Associated adaptor complex AP-2. Immunity 1997; 6: 583-589.
25. Qureshi OS, Kaur S, Hou TZ, et al. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem 2012; 287: 9429-9440.
26. Prado C, Gomez J, Lopez P, et al. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity. Immunobiology 2011; 216: 386-392.
27. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155-167.
28. Xia M, Gasser J, Feige U. Dexamethasone enhances CTLA-4 expression during T cell activation. Cell Mol Life Sci 1999; 55: 1649-1656.
29. Jago CB, Yates J, Camara NO, et al. differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol 2004; 136: 463-471.
30. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32.
31. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
32. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement. Leukemia 2011; 25: 749-760.
33. Menard C, Ghiringhelli F, Roux S, et al. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: Surrogate marker of efficacy of tremelimumab? Clin Cancer Res 2008; 14: 5242-5249.
34. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37: 473-484.
35. Ying H, Yang L, Qiao G, et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010; 185: 1375-1378.
36. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 78-88.
37. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063-6073.
38. Lutsiak M E, Semnani R T, D e Pascalis R, et al. Inhibition of CD4(-)25-T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868.
39. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117: 1605-1613.
40. Vieira P L, Christensen J R, Minaee S, et a l. I L-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4-CD25-regulatory T cells. J Immunol 2004; 172: 5986-5993.
41. Bryant CE, Brown RD, Yang S, et al. Ten year survivors of multiple myeloma demonstrate a differential expression of immunological biomarkers including a high incidence of cytotoxic T-cell clones which have not acquired myeloma-Associated anergy. Blood 2011; 118(Suppl. 1): Abstract 3924.
42. Giannopoulos K, Kaminska W, Hus I, et a l. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: Detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012; 106: 546-552.
43. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-1174.